Amphotericin B plus combination chemotherapy for extensive non-small cell bronchogenic carcinoma.
Sixteen patients with extensive non-small carcinoma of the lung were treated with methotrexate, vincristine, cyclophosphamide, and adriamycin. Cyclophosphamide and adriamycin were administered after pretreatment with amphotericin B. Amphotericin B-related toxicity was mild; cytotoxic chemotherapy-related toxicity was tolerable. The partial response rate was 12.5% and median survival was between 19 and 20 weeks. Response rate and survival were not superior to those of a similar drug combination lacking amphotericin B.
D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D000666:Amphotericin B